Sirnaomics

In News

Sirnaomics completes phase I trial of cancer drug STP707 and files clinical report with FDA - MSN

MSN - Jan 06, 2026

Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines - Yahoo Finance

Yahoo Finance - Sep 07, 2025

Sirnaomics Completes Phase I Trial of Cancer Drug STP707 and Files Clinical Report with FDA - TipRanks

TipRanks - Dec 22, 2025

How Sirnaomics Ltd. (V5Z) stock reacts to fiscal policies - Portfolio Return Report & Daily Growth Stock Investment Tips - ulpravda.ru

ulpravda.ru - Jan 08, 2026

Sirnaomics: a unique, clinical-phase RNA therapeutic innovator on the global stage - Nature

Nature - May 16, 2022

Sirnaomics Secures $105 Million in Series E Financing - PR Newswire

PR Newswire - Jul 01, 2021

Sirnaomics completes IND-enabling trials of siRNA therapy STP125G - Clinical Trials Arena

Clinical Trials Arena - Jul 15, 2024

How Sirnaomics Ltd. (V5Z) stock reacts to fiscal policies - Stop Loss & Advanced Technical Signal Analysis - ulpravda.ru

ulpravda.ru - Jan 08, 2026

Sirnaomics nabs a major $105M funding round for next stage of its RNA work - Fierce Biotech

Fierce Biotech - Oct 23, 2020

Sirnaomics starts 2022 with $64M Hong Kong IPO - BioWorld MedTech

BioWorld MedTech - Jan 04, 2022

Sirnaomics and Gore Range Capital Partner to Launch Sagesse Bio, an Aesthetic Medicine Company - World Business Outlook

World Business Outlook - Aug 01, 2024

Sirnaomics Ltd., the RNA Therapeutics Biopharmaceutical Company with Strong Presence in Both US and China, Successfully Listed on Main Board of SEHK - BioSpace

BioSpace - Dec 30, 2021

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment